Fuzuloparib Maintenance Therapy Prolonged Progression-Free Survival, Maintained Safety for Recurrent Ovarian Cancer

Article

Data presented at the Society of Gynecologic Oncology 2021 Annual Meeting on Women’s Cancer found a statistically significant benefit with fuzuloparib maintenance therapy compared with placebo for patients with platinum-sensitive, recurrent ovarian cancer.

Implementing fuzuloparib as maintenance therapy for patients with platinum-sensitive, recurrent ovarian cancer prolonged median progression-free survival (PFS) when compared with placebo, according to data from a phase 3 trial (NCT03863860) presented at the Society of Gynecologic Oncology (SGO) 2021 Virtual Annual Meeting on Women’s Cancer.

Patients experienced a benefit from fuzuloparib maintenance therapy regardless of germline BRCA1/2 status, and no further safety signals were observed in the analysis.

“Fuzuloparib as maintenance therapy achieved a statistically significant and clinically meaningful improvement in PFS for patients with platinum-sensitive, relapsed ovarian cancer compared with placebo regardless of BRCA mutation and had a manageable safety profile,” presenting author, Ning Li, MD, of the Cancer Hospital of Chinese Academy of Medical Sciences, explained in her presentation of the data.

The randomized, double-blind study assessed the efficacy and safety of fuzuloparib maintenance therapy for this cohort of patients. The population was randomized 2:1 to receive either 150 mg of fuzuloparib (n = 167) or placebo (n = 85) in 4-week cycles.

Eligible patients for the population had platinum-sensitive, relapsed, high-grade serious ovarian, fallopian tube, primary peritoneal, or endometrioid ovarian carcinoma. More, the patients received 2 or more previous platinum-based regimens and achieved a complete or partial response to their last treatment of that type.

The primary end point of the research was PFS assessed by a blinded independent review committee (BIRC). Key secondary end points included investigator-assessed PFS, chemotherapy-free interval, overall survival, safety, and objective response rate for patients with measurable disease at baseline.

The median PFS assessed by BIRC was 12.9 months (95% CI, 11.1-not reached [NR]) for patients receiving fuzuloparib compared with 5.5 months (95% CI, 3.8-5.6) for patients receiving placebo (HR, 0.25; 95% CI, 0.17-0.36; P < .0001). Regardless of BRCA mutation status, median PFS per BIRC assessment was longer for the fuzuloparib group than with placebo.

More, median investigator-assessed PFS showed similar data, with the fuzuloparib group at 12.9 months (95% CI, 11.1-NR) compared with 5.4 months (95% CI, 3.8-5.6) for the placebo group (HR, 0.27; 95% CI, 0.18-0.39; P < .0001).

“Previous phase 1 and phase 2 studies have revealed that fuzuloparib [at] 150 mg [twice daily] was well tolerated as [the recommended phase 2 dose] showed promising antitumor activity in patients with platinum-sensitive, recurrent ovarian cancer and germline BRCA mutations who had received prior 2 to 4 lines of chemotherapy,” Li said.

Focusing on one of the key secondary end points, the median chemotherapy-free interval was NR for patients in the fuzuloparib group and recorded at 11.6 months (95% CI, 8.8-NR) for the placebo group (HR, 0.30; 95%, 0.18-0.48; P < .0001).

Examining the safety profile of fuzuloparib compared with placebo, 48.5% of patients in the fuzuloparib group experienced grade 3 or higher adverse events (AEs) versus only 10.7% in the placebo group. Serious AEs were recorded in 10.8% and 3.8% of patients in the fuzuloparib and placebo groups, respectively. No treatment-related deaths were reported.

Phase 3 research focusing on fuzuloparib as first-line maintenance therapy to treat patients with newly diagnosed advanced ovarian cancer (NCT04229615) is ongoing, with a primary end point of IRC-assessed PFS.

Reference:

Li N, Zhang Y, Wang J, et al. Fuzuloparib maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer: A multicenter, randomized, double-blind, placebo-controlled, phase III trial. Presented at: 2021 Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer. Abstract 11557.

Recent Videos
Medical use of AI increases every day, and in the future, will be exponentially greater and many forms of treatment will be improved, according to Russell C. Langan, MD, FACS, FSSO.
Shubham Pant, MD, MBBS, highlights an “exciting time” in the treatment of patients with RAS-mutated pancreatic cancer.
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
A computational linguistics model designed to locate pancreatic cysts that started to locate pancreatic cancer has the potential to lead to more efficient treatment.
Brett L. Ecker, MD, discusses the importance of multidisciplinary collaboration in improving patient outcomes in neuroendocrine tumors.
A computational linguistics model has mitigated disparities in surveillance of the pancreas that primarily affected racial and ethnic minorities.
Related Content